The MicroRNA Landscape of MYCN-Amplified Neuroblastoma.
Danny Misiak,Sven Hagemann,Jessica L. Bell,Bianca Busch,Marcell Lederer,Nadine Bley,Johannes H. Schulte,Stefan Hüttelmaier +7 more
TLDR
In this paper, the miRNome of 97 neuroblastoma-derived cells was analyzed using microRNA trapping by RNA affinity purification to reveal the MYCN-dependent miRNOME.Abstract:
MYCN gene amplification and upregulated expression are major hallmarks in the progression of high-risk neuroblastoma. MYCN expression and function in modulating gene synthesis in neuroblastoma is controlled at virtually every level, including poorly understood regulation at the post-transcriptional level. MYCN modulates the expression of various microRNAs including the miR-17-92 cluster. MYCN mRNA expression itself is subjected to the control by miRNAs, most prominently the miR-17-92 cluster that balances MYCN expression by feed-back regulation. This homeostasis seems disturbed in neuroblastoma where MYCN upregulation coincides with severely increased expression of the miR-17-92 cluster. In the presented study, we applied high-throughput next generation sequencing to unravel the miRNome in a cohort of 97 neuroblastomas, representing all clinical stages. Aiming to reveal the MYCN-dependent miRNome, we evaluate miRNA expression in MYCN-amplified as well as none amplified tumor samples. In correlation with survival data analysis of differentially expressed miRNAs, we present various putative oncogenic as well as tumor suppressive miRNAs in neuroblastoma. Using microRNA trapping by RNA affinity purification, we provide a comprehensive view of MYCN-regulatory miRNAs in neuroblastoma-derived cells, confirming a pivotal role of the miR-17-92 cluster and moderate association by the let-7 miRNA family. Attempting to decipher how MYCN expression escapes elevated expression of inhibitory miRNAs, we present evidence that RNA-binding proteins like the IGF2 mRNA binding protein 1 reduce miRNA-directed downregulation of MYCN in neuroblastoma. Our findings emphasize the potency of post-transcriptional regulation of MYCN in neuroblastoma and unravel new avenues to pursue inhibition of this potent oncogene.read more
Citations
More filters
Journal ArticleDOI
MYCN in Neuroblastoma: "Old Wine into New Wineskins".
TL;DR: In this article, the role of BHLH Transcription factor (myCN) in neuroblastoma has been investigated from all possible mechanistic sites, including the references of myCN in the literature, the gene's anatomy along with its transcripts, the protein's anatomy, the epigenetic mechanisms regulating MYCN expression and function, as well as MYCN amplification.
Journal ArticleDOI
miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma
Anup Singh Pathania,Philip Prathipati,Omalla A. Olwenyi,Srinivas Chava,OgheneTejiri V. Smith,Subash C. Gupta,Nagendra K. Chaturvedi,Siddappa N. Byrareddy,Don W. Coulter,Kishore B. Challagundla +9 more
TL;DR: In this paper , the role of micro RNAs in anti-tumor immune response via a range of data-driven workflows and in vitro & in vivo experiments was explored.
Journal ArticleDOI
A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment.
Jenny Shim,Kelly C. Goldsmith +1 more
TL;DR: In this article, the authors focus on the role of YAP in neuroblastoma and further describe its demonstrated and potential effects on the solid tumor microenvironment (TME) and discuss the therapeutic strategies for inhibiting YAP.
Journal ArticleDOI
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
Damiano Bartolucci,Luca Montemurro,Salvatore Raieli,Silvia Lampis,Andrea Pession,Patrizia Hrelia,Roberto Tonelli +6 more
TL;DR: The aim of this review is to describe the current knowledge in the diagnosis, prognosis and therapeutic approaches of HR-NB, particularly in relation to MYCN, to highlight how MYCN influences the HR- NB scenario and the new therapeutic approaches that are currently proposed to target it.
Journal ArticleDOI
IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression
Sven Hagemann,Danny Misiak,Jessica L. Bell,Tommy Fuchs,Marcell Lederer,Nadine Bley,Monika Hämmerle,Ehab Ghazy,Wolfgang Sippl,Johannes Schulz,Stefan Hüttelmaier +10 more
TL;DR: In this article , a druggable neuroblastoma oncogene circuit settling on strong, transcriptional/post-transcriptional synergy of MYCN and IGF2BP1 was investigated.
References
More filters
Journal ArticleDOI
Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice.
Simon Müller,Alice Wedler,Janina Breuer,Markus Glaß,Nadine Bley,Marcell Lederer,Jacob Haase,Claudia Misiak,Tommy Fuchs,Alina Ottmann,Tessa Schmachtel,Lyudmila A. Shalamova,Alexander Ewe,Achim Aigner,Oliver Rossbach,Stefan Hüttelmaier +15 more
TL;DR: It is demonstrated that PEI/decoy nanoparticles lead to a significant inhibition of tumor growth in a lung adenocarcinoma xenograft mouse model via the upregulation of tumor suppressor expression.
Journal ArticleDOI
LIN28B: an orchestrator of oncogenic signaling in neuroblastoma.
TL;DR: This work analyzed gene expression data from neuroblastoma primary tumors and identified a strong positive correlation between LIN28B expression and RAN (RAS-related nuclear protein) signaling, and demonstrated that neuroblastomas with 12q gain were associated with increased RAN expression, suggesting that somatic gain might represent another means of driving RANexpression.
Posted ContentDOI
IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer
Nadine Bley,A. Schott,S. Mueller,Danny Misiak,Marcell Lederer,Tommy Fuchs,C. Assmann,M. Glass,Christian Ihling,Andrea Sinz,Nikolaos Pazaitis,Claudia Wickenhauser,Martina Vetter,O Ungurs,Hans-Georg Strauss,Christoph Thomssen,S. Huettelmaier +16 more
TL;DR: It is shown, that the IGF2 mRNA binding protein 1 (IGF2BP1) is up-regulated in mesenchymal-like HG-SOC and promotes SRC activation by a previously unknown protein-ligand-induced, but RNA-independent mechanism, which reveals a post-transcriptional mechanism of interconnected stimulation of SRC/ERK signaling in ovarian cancer cells.